加载中
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
前收盘价
US$1.94
−US$0.01 · -0.51%
盘中时间采用ET。市场数据可能有所延迟。
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
日内区间
当前US$1.94
52周区间
当前US$1.94
盘中时间采用ET。市场数据可能有所延迟。
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
日内区间
当前US$1.94
52周区间
当前US$1.94
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 1588.7万 USD | 396.92万 USD | 2247.15万 USD | — | — |
| 毛利 | −1588.7万 USD | −396.92万 USD | −2247.15万 USD | — | — |
| 研究与开发 | 1588.7万 USD | 1816.15万 USD | 2247.15万 USD | 2535.53万 USD | 2310.89万 USD |
| 销售、一般及管理费用 | 892.28万 USD | 422.18万 USD | 900.46万 USD | 1070.74万 USD | 1308.52万 USD |
| 营业费用 | 892.28万 USD | 2238.33万 USD | 900.46万 USD | 3606.28万 USD | 3619.41万 USD |
| 利息支出 | 64.89万 USD | 74.57万 USD | 67.54万 USD | 108.1万 USD | 114.93万 USD |
| 折旧和摊销 | 388.52万 USD | 396.92万 USD | 395.83万 USD | 382.89万 USD | 223.11万 USD |
| 营业利润 | −2480.97万 USD | −2635.25万 USD | −3147.61万 USD | −3606.28万 USD | −3619.41万 USD |
| 净利润 | −2541.11万 USD | −2692.05万 USD | −3236.59万 USD | −3670.07万 USD | −3636.11万 USD |
公司数据更新于 2026年10月11日。
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 1996年8月28日 | US$0.0083Irregular | — | — |
除息 1996年8月28日
US$0.0083
Irregular
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
